BioXcel Therapeutics Added to Russell 3000® Index
01 juil. 2019 08h00 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., July 01, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced that the company has been added to the broad-market Russell 3000® Index...
BioXcel Therapeutics to Participate in the BMO 2019 Prescriptions for Success Healthcare Conference
18 juin 2019 08h00 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., June 18, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will...
BioXcel Therapeutics Completes Dosing Two Cohorts of Agitated Schizophrenia Patients with BXCL501 in a Phase 2 Efficacy Trial
10 juin 2019 08h00 HE
|
BioXcel Therapeutics, Inc.
Total of 96 agitated patients and healthy volunteers have received multiple doses of BXCL501, a proprietary sublingual thin film On track to announce top line results from Phase 2 efficacy trial in...
BioXcel Therapeutics CEO, Dr. Vimal Mehta to Participate in BIO International Convention Panel on Innovative Clinical Trial Designs
06 juin 2019 08h00 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., June 06, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), announced today that Dr. Vimal Mehta, Chief Executive Officer and Founder of BTI,...
BioXcel Therapeutics Announces FDA Clearance of IND Application for Triple Combination in Pancreatic Cancer and CTA Acceptance for Double Combination in Aggressive Form of Prostate Cancer (tNEPC) for Lead Immuno-Oncology Program, BXCL701
03 juin 2019 08h00 HE
|
BioXcel Therapeutics, Inc.
• FDA clearance of IND for BXCL701 triple combination therapy with Nektar’s bempegaldesleukin and BAVENCIO® (avelumab, Merck KGaA, Darmstadt, Germany and Pfizer) in pancreatic cancer • MHRA (U.K....
BioXcel Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference
31 mai 2019 16h05 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., May 31, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence...
BioXcel Therapeutics Achieved Targeted Exposures of BXCL501 Designed For Non-Invasive Acute Treatment of Agitation in Neuropsychiatric Diseases
20 mai 2019 07h30 HE
|
BioXcel Therapeutics, Inc.
Phase 2 efficacy trial in agitated schizophrenia patients anticipated to commence imminently BXCL501 is a potential first-in-class selective alpha-2a receptor agonist, formulated as a proprietary...
BioXcel Therapeutics to Highlight Advances in the BXCL501 Program at 2019 Investor Event in New York City
13 mai 2019 08h00 HE
|
BioXcel Therapeutics, Inc.
Management to unveil BXCL501 global development strategy and agitation franchise expansion Key Opinion Leaders to discuss acute agitation across multiple disease conditions Webcast scheduled from...
BioXcel Therapeutics to Present at the 2019 UBS Global Healthcare Conference
09 mai 2019 08h00 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., May 09, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced, that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present...
BioXcel Therapeutics Reports First Quarter 2019 Results and Provides Business Update
07 mai 2019 08h00 HE
|
BioXcel Therapeutics, Inc.
On track to announce results in May 2019 from recently completed BXCL501 Phase 1 pharmacokinetic (bioavailability) and safety study Advanced manufacturing of BXCL501 thin film formulation for pivotal...